The best-documented mechanism of resistance in prostate cancer is acquired BRCA2 reversion mutations, where previously BRCA2-deficient tumor cells can achieve BRCA2 proficiency due to constant selective pressure of PARP inhibition. Here, BRCA2 is linked to neoplasm.